NORTH AMERICA DRY EYE DISEASE MARKET FORECAST 2023-2032

The North America dry eye disease market growth analysis includes the evaluation of Canada and the United States. In the United States, as per a National Health and Wellness Survey, 6.8% of the adult population has dry eye disease. The prevalence rises with age and is greater in females than males. For instance, another data analysis from the United States National Health and Wellness Survey (NHWS, 2017) reveals that gender differences with regard to the prevalence of dry eye disease increased with age. As a result, healthcare practitioners are anticipating an increase in dry eye syndromes among the aging population. 

Moreover, product launches and developments by key players are set to enhance market prospects. For instance, in 2022, Bausch + Lomb presented data from the second pivotal phase 3 trial of investigational treatment NOV03. It would be the first pharmaceutical therapy available in the United States with a new mechanism of action designed to alleviate symptoms of dye eye disease associated with Meibomian gland dysfunction.  

The North America dry eye disease market scope includes type, product, and distribution channel. The type segment includes prescription and OTC.

Non-prescription eye drops can be purchased over the counter. These offer temporary relief from dry eye symptoms. Most over-the-counter (OTC) eye drops contain humectants, which help in the retention of lubricants, moisture, and electrolytes like potassium. They are relatively more affordable compared to prescription medications. However, most OTC dry eye drops work on the aqueous layer of the tear film, which offers limited relief from dry eye disease.

At the same time, several eye drops contain non-blurring lubricant mixes that offer long-lasting relief from symptoms of dry eye disease like burning and stinging brought on by prolonged contact lens wear, excessive digital media use, dry indoor or outdoor settings, hormonal changes, and laser eye surgery. As a result, the easy availability and affordability of OTC drugs are expected to drive the OTC segment’s growth. 

However, patients are encouraged to see an eye professional if OTC artificial tears do not render the desired results. Accordingly, prescription eye drops prescribed by doctors help treat chronic eye conditions. Age, prolonged contact lens wear, environmental conditions, medication, and age are among the leading causes of dry eyes. These can be managed using prescriptive medical products. 

The anti-inflammatory drugs category of the product segment includes corticosteroid, cyclosporine, and other anti-inflammatory drugs. The other anti-inflammatory drugs include the new drug lymphocyte function-associated antigen 1 (LFA-1) antagonists. Whereas Xiidra is the only US FDA-approved drug in this class. Theoretically, it blocks the interaction between LFA-1 and its aligned intracellular adhesion molecule-1 (ICAM-1).

Some of the key firms operating in the North America dry eye disease market are Novartis AG, Novaliq GmbH, Lumenis, OASIS Medical, etc.

OASIS Medical Inc is a specialty manufacturer of surgical supplies, instruments, disposables, and eye care products. It has been manufacturing a vast range of products for use in retinal disease, dry eye disease, refractive error, and cataracts. The company has its headquarters in Los Angeles, California, the United States. 

One of its key products, Oasis TEARS® PF PLUS Preservative-Free Lubricant Eye Drops, prevents dry eye with its viscoadaptove and adherence qualities.